Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Normand E. Allaire; Uta Griesenbach; Batsheva Kerem; John D. Lueck; Noemie Stanleigh; Yifat S. Oren

doi:10.1016/j.jcf.2022.12.016

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Normand E. Allaire^*, Uta Griesenbach, Batsheva Kerem, John D. Lueck, Noemie Stanleigh, Yifat S. Oren

^*Corresponding author for this work

Department of Genetics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).

Original language	American English
Pages (from-to)	S39-S44
Journal	Journal of Cystic Fibrosis
Volume	22
DOIs	https://doi.org/10.1016/j.jcf.2022.12.016
State	Published - Mar 2023

Bibliographical note

Funding Information:
This research was supported (in part) by grants to B.K from the Cystic Fibrosis Foundation , (grant no. KEREM15XX0 and KEREM21GO ), the Ministry of science and Technology (grant no. 3–17632 ) and the Israel Science Foundation (grant no. 2039/20 ) within the Israel Precision Medicine Partnership program and Cystic Fibrosis Foundation Research Grant ( LUECK18GO ) and NIH grant ( 1 R01 HL153988-02A1 ) to J.D.L.

Funding Information:
This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS).

Funding Information:
John D. Lueck sits on the Scientific Advisory Boards for HcBioscience and The Cystic Fibrosis Foundation. Batsheva Karem is the CSO of SpliSense and Professor of Genetics in the Hebrew University, Jerusalem, Israel. Yifat is the Director of Discovery at SpliSense. This research was supported in part by Boehringer Ingelheim, Germany (BI), and BI was given the opportunity to review this presentation for medical and scientific accuracy as it relates to BI substances, as well as intellectual property considerations.

Publisher Copyright:
© 2023 European Cystic Fibrosis Society

Keywords

ASO
Cystic Fibrosis
Delivery
Gene
RNA
Therapeutic

Access to Document

10.1016/j.jcf.2022.12.016

Cite this

@article{73f7d23601da4128b1584ed2c13d353f,

title = "Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis",

abstract = "Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).",

keywords = "ASO, Cystic Fibrosis, Delivery, Gene, RNA, Therapeutic",

author = "Allaire, {Normand E.} and Uta Griesenbach and Batsheva Kerem and Lueck, {John D.} and Noemie Stanleigh and Oren, {Yifat S.}",

note = "Funding Information: This research was supported (in part) by grants to B.K from the Cystic Fibrosis Foundation , (grant no. KEREM15XX0 and KEREM21GO ), the Ministry of science and Technology (grant no. 3–17632 ) and the Israel Science Foundation (grant no. 2039/20 ) within the Israel Precision Medicine Partnership program and Cystic Fibrosis Foundation Research Grant ( LUECK18GO ) and NIH grant ( 1 R01 HL153988-02A1 ) to J.D.L. Funding Information: This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS). Funding Information: John D. Lueck sits on the Scientific Advisory Boards for HcBioscience and The Cystic Fibrosis Foundation. Batsheva Karem is the CSO of SpliSense and Professor of Genetics in the Hebrew University, Jerusalem, Israel. Yifat is the Director of Discovery at SpliSense. This research was supported in part by Boehringer Ingelheim, Germany (BI), and BI was given the opportunity to review this presentation for medical and scientific accuracy as it relates to BI substances, as well as intellectual property considerations. Publisher Copyright: {\textcopyright} 2023 European Cystic Fibrosis Society",

year = "2023",

month = mar,

doi = "10.1016/j.jcf.2022.12.016",

language = "American English",

volume = "22",

pages = "S39--S44",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

}

TY - JOUR

T1 - Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

AU - Allaire, Normand E.

AU - Griesenbach, Uta

AU - Kerem, Batsheva

AU - Lueck, John D.

AU - Stanleigh, Noemie

AU - Oren, Yifat S.

N1 - Funding Information: This research was supported (in part) by grants to B.K from the Cystic Fibrosis Foundation , (grant no. KEREM15XX0 and KEREM21GO ), the Ministry of science and Technology (grant no. 3–17632 ) and the Israel Science Foundation (grant no. 2039/20 ) within the Israel Precision Medicine Partnership program and Cystic Fibrosis Foundation Research Grant ( LUECK18GO ) and NIH grant ( 1 R01 HL153988-02A1 ) to J.D.L. Funding Information: This paper is part of a supplement supported by the European Cystic Fibrosis Society (ECFS). Funding Information: John D. Lueck sits on the Scientific Advisory Boards for HcBioscience and The Cystic Fibrosis Foundation. Batsheva Karem is the CSO of SpliSense and Professor of Genetics in the Hebrew University, Jerusalem, Israel. Yifat is the Director of Discovery at SpliSense. This research was supported in part by Boehringer Ingelheim, Germany (BI), and BI was given the opportunity to review this presentation for medical and scientific accuracy as it relates to BI substances, as well as intellectual property considerations. Publisher Copyright: © 2023 European Cystic Fibrosis Society

PY - 2023/3

Y1 - 2023/3

N2 - Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).

AB - Most people with Cystic Fibrosis (PwCF) harbor Cystic Fibrosis Transmembrane Conductance (CFTR) mutations that respond to highly effective CFTR modulators (HEM); however, a small fraction of non-responsive variants will require alternative approaches for treatment. Furthermore, the long-term goal to develop a cure for CF will require novel therapeutic strategies. Nucleic acid-based approaches offer the potential to address all CF-causing mutations and possibly a cure for all PwCF. In this minireview, we discuss current knowledge, recent progress, and critical questions surrounding the topic of Gene-, RNA-, and ASO-based therapies for the treatment of Cystic Fibrosis (CF).

KW - ASO

KW - Cystic Fibrosis

KW - Delivery

KW - Gene

KW - RNA

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85149183999&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2022.12.016

DO - 10.1016/j.jcf.2022.12.016

M3 - Article

C2 - 36658041

AN - SCOPUS:85149183999

SN - 1569-1993

VL - 22

SP - S39-S44

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

ER -

Gene, RNA, and ASO-based therapeutic approaches in Cystic Fibrosis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this